In the last trading session, 2.13 million Sutro Biopharma Inc (NASDAQ:STRO) shares changed hands as the company’s beta touched 1.09. With the company’s per share price at $2.76 changed hands at $0.01 or 0.36% during last session, the market valuation stood at $227.58M. STRO’s last price was a discount, traded about -122.1% off its 52-week high of $6.13. The share price had its 52-week low at $2.45, which suggests the last value was 11.23% up since then. When we look at Sutro Biopharma Inc’s average trading volume, we note the 10-day average is 1.05 million shares, with the 3-month average coming to 670.15K.
Analysts gave the Sutro Biopharma Inc (STRO) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.18. If we narrow down to specifics, the data shows that 0 out of 5 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended STRO as a Hold, 5 felt it is a Buy and 0 rated the stock as Underweight. Sutro Biopharma Inc’s EPS for the current quarter is expected to be -0.95.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Sutro Biopharma Inc (NASDAQ:STRO) trade information
Instantly STRO was in green as seen at the end of in last trading. With action 5.75%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -35.66%, with the 5-day performance at 5.75% in the green. However, in the 30-day time frame, Sutro Biopharma Inc (NASDAQ:STRO) is -22.25% down. Looking at the short shares, we see there were 1.79 million shares sold at short interest cover period of 3.26 days.
The consensus price target for the stock as assigned by Wall Street analysts is 11, meaning bulls need an upside of 74.91% from its current market value. According to analyst projections, STRO’s forecast low is 8 with 15 as the target high. To hit the forecast high, the stock’s price needs a -443.48% plunge from its current level, while the stock would need to soar -189.86% for it to hit the projected low.
Sutro Biopharma Inc (STRO) estimates and forecasts
Data shows that the Sutro Biopharma Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -30.65% over the past 6 months, a -52.88% in annual growth rate that is considerably lower than the industry average of 17.60%. Year-over-year growth is forecast to reach -61.49% down from the last financial year.
Consensus estimates given by 11 financial analysts project the company’s revenue in the current quarter to hit an average of 12.18M. 5 analysts are of the opinion that Sutro Biopharma Inc’s revenue for the current quarter will be 10.81M. The company’s revenue for the corresponding quarters a year ago was 113.72M and 13.01M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -89.29%. The estimates for the next quarter sales put growth at -16.91%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 21.96%. The 2024 estimates are for Sutro Biopharma Inc earnings to decrease by -63.07%.
STRO Dividends
Sutro Biopharma Inc is expected to release its next quarterly earnings report in January.
Sutro Biopharma Inc (NASDAQ:STRO)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0.96% of Sutro Biopharma Inc shares while 77.16% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 77.91%. There are 77.16% institutions holding the Sutro Biopharma Inc stock share, with BLACKROCK INC. the top institutional holder. As of 2024-06-30, the company held 11.2447% of the shares, roughly 6.91 million STRO shares worth $20.25 million.
SUVRETTA CAPITAL MANAGEMENT, LLC holds the second largest percentage of outstanding shares, with 9.4906% or 7.71 million shares worth $22.59 million as of 2024-06-30.
